Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences

Lenacapavir, a first-in-class HIV capsid inhibitor, is under development by Gilead Sciences for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). This article responds to inquiries into Gilead's access efforts for low- and lower-middle-income countries and reviews the science behind lenacapavir and its investigational use for HIV prevention, the current state of Gilead's planning for equitable access, and the necessity for partnership to end the HIV epidemic. Clinical trial results are a culmination of years of dedicated science, and they are just the beginning; we look forward to sharing updates as milestones are reached. Gilead is committed to working with scientists, clinicians, communities, advocates, governments, and other stakeholders to achieve broad, sustainable global access to lenacapavir for HIV prevention, if approved. Lenacapavir holds potential for helping to end new HIV infections around the world, a potential that reflects the vision we have at Gilead: to end the HIV epidemic for everyone, everywhere.